The Developmental Research Program (DRP) of the University of Texas SPORE in Lung Cancer is an integral part of the overall Lung Cancer SPORE research. This Program provides, after selection by external review and applicant discussion with senior SPORE investigators, a flexible and nimble platform for seed funding of novel research that have potential to significantly impact lung cancer translational research. It is designed to fund promising early stage projects that address important translational objectives in early detection, prevention, and therapy of lung cancer. Through institutional commitments at both UTSW and UTMDACC there are $300,000 in funds (that can be used for DRP or CDP Projects) matched to the $50,000 DRP funds provided by the grant. The DRP program has evolved into a highly structured process for solicitation, evaluation and collaboration with skilled scientists inside and outside UTSW and UTMDACC institutions. We want to attract new investigators to lung cancer translational research who have novel approaches and techniques that address significant barriers in lung cancer and which could benefit from SPORE Core Resources, interaction and mentorship, and that have potential to synergize with our existing Projects. The DRP has resulted in a large number of publications, new lung cancer translational scientists, and new peer reviewed grants. We have the following Specific Aims: 1. Provide Development Project funding to projects focused on lung cancer translational research. 2. Use the expertise of UTSW and MDACC scientific and clinical leaders and SPORE investigators and Core leaders to identify high impact lung cancer translational projects in the UTSW, UTMDACC and related environments. 3. Build on well-established SPORE mechanisms for mentorship of and integration with SPORE investigators, Projects, and Cores. 4. Build on the existing SPORE framework to promote communication between basic and clinical scientists, within and outside UTSW and UTMADCC, across disciplines, and guide the training of a new generation of translational researchers. 5. Facilitate development and transition of these successful projects into competitive applications for peer-reviewed funding. 6. Build on existing SPORE mechanisms to translate the findings into the clinic.

Public Health Relevance

Over the last 20 years, the 5-year survival rate for lung cancer has improved only by 2%, from 13 percent to 15 percent. That statistics alone is an urgent call for accelerated translational lung cancer research. The primary objective of the DRP is to provide a source of seed funding to 1) support innovative and meritorious Lung (Dancer projects within and outside UTSW and UTMDACC;2) establish functional collaborative networks;and 3) recruit highly qualified new investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-16A1
Application #
8747092
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
1996-09-30
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$76,649
Indirect Cost
$15,359
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Zhang, Liren; Lin, Jing; Ye, Yuanqing et al. (2018) Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther 103:1061-1073
Bayo, Juan; Tran, Tram Anh; Wang, Lei et al. (2018) Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Cell Rep 25:1040-1050.e5
Ludlow, Andrew T; Wong, Mandy Sze; Robin, Jerome D et al. (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112
Chen, Limo; Diao, Lixia; Yang, Yongbin et al. (2018) CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8:1156-1175
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49

Showing the most recent 10 out of 1059 publications